3-Feb-2022	Maxim Group: Studies on Track, Cash through YE22

7-Dec-2021	H.C. Wainwright & Co. - Phase 2 In Line With Expectations; A Catalyst-Rich 2022

6-Dec-2021	Bell Potter - Headline Data - 3 Month Survival Benefit

3-Dec-2021	Maxim Group: Final P2 Paxalisib Data Largely Incremental; More Pax Data in 2022

14-Oct-2021	Maxim Group: Equity Research Initiation on Kazia

13-Oct-2021	Edison Research: Multiple paxalisib data points expected in Q4

10-May-2021	Bell Potter: Kazia Therapeutics - New In-license deal

21-Apr-2021	Corporate Connect: Another Deal – Kazia Inlicences New Anti-Cancer Med From Highly Impressive Partner

21-Apr-2021	H.C. Wainwright: Expanding Pipeline With EVT801 In-License; Reiterate Buy

20-Apr-2021	Edison Research: New asset to target tumor lymphangiogenesis

30-Mar-2021	Bell Potter: Kazia Therapeutics - China Out License Deal

2-Mar-2021	Corporate Connect: Cantrixil licensed To Oasmia Pharmaceuticals & Kazia Shareholders Learn a Positive Lesson About Kazia

2-Mar-2021	Edison Research: All in on GBM AGILE, but eyes on brain mets

5-Jan-2021	HC Wainwright: A Unique PI3K Inhibitor for Brain Tumors; Initiate With Buy and $17 PT

15-Dec-2020	Bell Potter: Kazia Therapeutics - Paxalisib Joins A Second Platform Study

11-Dec-2020	Cantrixil final Phase I data reported (ADR update)

10-Dec-2020	Edison Research: Cantrixil final Phase I data reported

2-Dec-2020	Edison Research: Phase IIa shows good safety, consistent efficacy (ADR update)

25-Nov-2020	Edison Research: Phase IIa shows good safety, consistent efficacy

18-Nov-2020	Corporate Connect: Kazia Therapeutics - SNO Presentations: Late-Interim Results from Phase II GBM & Phase I DIPG Studies Released

18-Nov-2020	Bell Potter: Kazia Therapeutics (KZA) - Results Unlikely Due To Chance

2-Nov-2020	Bell Potter: Kazia Therapeutics - GBM Agile In More Detail

14-Oct-2020	Corporate Connect: Kazia Therapeutics - A Laser-Like Focus on Adding Value - 5 Data Readouts in 9-Months

12-Oct-2020	Bell Potter: Kazia Therapeutics - Approval Study Substantially Funded

27-Aug-2020	Bell Potter: Kazia Therapeutics - Strength To Strength

13-Aug-2020	Edison Research: Kazia Therapeutics - Bringing a vetted drug class to the brain

3-Jul-2020	Bell Potter: Kazia Therapeutics - 5 month survival extension

31-Mar-2020	Edison Research: Paxalisib trial still on track for H220 start

13-Jan-2020	Edison Research: An agile pivot

13-Jan-2020	Edison Research: An agile pivot (ADR Update)

2-Dec-2019	Edison Research: GDC-0084 – encouraging initial efficacy (ADR Update)

25-Nov-2019	Edison Research: GDC-0084 – encouraging initial efficacy

5-Sep-2019	Edison Research - GDC-0084 gets a fifth collaboration

23-Jun-2019	Edison Research - Higher MTD, new collaboration for GDC-0084

21-Jun-2019	Edison Research: Higher MTD, new collaboration for GDC-0084 (ADR Outlook)

1-Apr-2019	Edison Research: Cantrixil efficacy data presented at AACR (ADR Update)

1-Apr-2019	Edison Research - Cantrixil efficacy data presented at AACR

31-Oct-2018	Morgans interview with Kazia CEO Dr James Garner

31-Oct-2018	Edison Research - New indications for GDC-0084

29-Oct-2018	Edison Research: New indications for GDC-0084 (ADR Update)

24-Sep-2018	Edison Research - GDC-0084 and Cantrixil trials progressing

20-Sep-2018	Edison Research:GDC-0084 and Cantrixil trials progressing (ADR update)

14-May-2018	Edison Research - GDC-0084 Phase II underway

11-May-2018	Edison Research: GDC-0084 Phase II underway (ADR Outlook)

3-Apr-2018	NDF Research Re-initiates Research Coverage on Kazia Therapeutics

21-Dec-2017	Edison Research: GDC-0084 Phase II to begin shortly (ADR Update)

14-Dec-2017	Cedrus Investments - Kazia Therapeutics Targeting Unmet Oncological Needs

7-Nov-2017	NDF Research Initiates Research Coverage on Novogen

11-Sep-2017	Edison Research: GDC-0084 Phase II on track to commence Q417 (ADR Update)

11-Sep-2017	Edison Research - GDC-0084 Phase II on track to commence Q417

25-May-2017	Edison Research: Anisina nixed, GDC-0084 on track for Phase II (ADR Outlook)

22-May-2017	Edison research - Anisina nixed, GDC-0084 on track for Phase II

31-Oct-2016	Edison research – Novogen Acquires Mid-Stage Cancer Drug from Genentech

27-Sep-2016	H.C. Wainwright & Co Report – New Strategy in Place

11-May-2016	Edison Research: Cantrixil to enter clinic in H216 (ADR Update)

9-May-2016	Edison Report - Cantrixil to enter clinic in H216